Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: General Population Clear all
Completed Not applicable Interventional

Sleep, Mood, and Behavior Study

NCT00787397
View directory record Official record
Conditions
Sleep Difficulties in Pediatric Anxiety Disorder, Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Phobia
Interventions
Cognitive Behavioral Therapy-Sleep
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
9 Years to 14 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Open Trial of an ACT Skills Group and Mobile App for Worry

NCT03709433
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ACT groups and mobile app
Behavioral
Lead sponsor
Utah State University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 27, 2026, 7:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Racial Disparities in the Expression of Paranoia

NCT07460453
View directory record Official record
Conditions
Paranoia, Psychotic Disorders
Interventions
Guided Visual Imagery Task
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

NCT00314210
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
56
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

NCT03304054
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Amifampridine Phosphate, Placebo Oral Tablet
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

NCT01871402
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
000-0551 Lotion, Vehicle Lotion
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Arlington Heights, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 27, 2026, 7:41 AM EDT
Completed No phase listed Observational

Use of Virtual Reality to Communicate Concepts of Genomics to the General Public

NCT00316056
View directory record Official record
Conditions
Healthy, Learning, Communication
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 40 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 7:41 AM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 27, 2026, 7:41 AM EDT
Recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07767903
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Redlands, California • Orlando, Florida • Watertown, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 7:41 AM EDT
Terminated Not applicable Interventional

Long-term Cardiac Monitoring in Epilepsy

NCT03955432
View directory record Official record
Conditions
Focal Epilepsy, Intractable Epilepsy, Epileptic Encephalopathy, Lennox Gastaut Syndrome, Symptomatic Epilepsy, Generalized Epilepsy
Interventions
Reveal LINQ ICM System
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 27, 2026, 7:41 AM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 3 Interventional

A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

NCT00236054
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Gabitril
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 27, 2026, 7:41 AM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen, Sham Comparator
Drug · Other
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

NCT00329446
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Quetiapine Fumarate, Escitalopram oxylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Not applicable Interventional

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

NCT00002048
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 7:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay

NCT04816175
View directory record Official record
Conditions
Microcephaly, Hyperkinesis With Developmental Delay, Global Developmental Delay
Interventions
Acquire Therapy
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
6 Months to 15 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of Social Network Targeting in Honduras

NCT02694679
View directory record Official record
Conditions
Preterm Delivery, Hypothermia, Diarrhea, Upper Respiratory Infection, Omphalitis
Interventions
CBNH
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Years and older
Enrollment
31,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 27, 2026, 7:41 AM EDT
Not listed Not applicable Interventional

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

NCT01687764
View directory record Official record
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions
Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention
Other · Behavioral
Lead sponsor
Hospital de Clinicas de Porto Alegre
Other
Eligibility
7 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00730691
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vortioxetine, Duloxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
66
States / cities
Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Not applicable Interventional Results available

Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study

NCT00689091
View directory record Official record
Conditions
Awareness During General Anesthesia
Interventions
Bispectral Index Monitor, Electronic MAC alert
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
22,185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 27, 2026, 7:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sleep and Breathing in the General Population - Chemical Stimuli

NCT04720547
View directory record Official record
Conditions
Sleep-disordered Breathing
Interventions
Zolpidem, No Treatment
Drug · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 27, 2026, 7:41 AM EDT